- Verve Therapeutics Announces Updates on its PCSK9 Program
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
- Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
- Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
- Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
- Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.59 |
---|---|
High | 6.80 |
Low | 6.50 |
Bid | 6.51 |
Offer | 6.53 |
Previous close | 6.66 |
Average volume | 1.15m |
---|---|
Shares outstanding | 83.62m |
Free float | 77.22m |
P/E (TTM) | -- |
Market cap | 556.90m USD |
EPS (TTM) | -3.13 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 17:58 BST.
More ▼